BlackRock’s Kailera Therapeutics KLRA Stock Holding History

BlackRock’s Portfolio KLRA Stock Details KLRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$86.5M	Buy	+3,928,604	New	+$86.4M	﹤0.01%	2307

Other funds holding KLRA

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

BlackRock's KLRA Position: Q2 2026 in Review

BlackRock opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 3,928,604 shares worth $86.5M. The stake represents ﹤0.01% of the portfolio and ranks #2307 among its holdings.

24 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

BlackRock held 3,928,604 shares of Kailera Therapeutics worth $86.5M as of Q2 2026.
Kailera Therapeutics was a new BlackRock position in Q2 2026.
Kailera Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2307 holding.
24 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.